Virtus ETF Advisers LLC Prelude Therapeutics Inc Transaction History

Virtus ETF Advisers LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$5.0 - $8.82 $875 - $1,543	175 Added 0.73%	24,180 $160,000
Q2 2022 Aug 12, 2022	BUY	$4.0 - $7.55 $43,828 - $82,725	10,957 Added 83.97%	24,005 $125,000
Q1 2022 May 16, 2022	SELL	$6.9 - $13.22 $5,292 - $10,139	-767 Reduced 5.55%	13,048 $90,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $89,448 - $238,780	7,523 Added 119.56%	13,815 $172,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $38.65 $8,507 - $12,754	-330 Reduced 4.98%	6,292 $197,000
Q2 2021 Aug 10, 2021	BUY	$28.63 - $44.3 $189,587 - $293,354	6,622 New	6,622 $190,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.